array:20 [
  "pii" => "X2013251408033088"
  "issn" => "20132514"
  "doi" => " "
  "estado" => "S300"
  "fechaPublicacion" => "2008-04-01"
  "documento" => "article"
  "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/"
  "subdocumento" => "fla"
  "cita" => "Nefrologia (English Version). 2008;28:123-8"
  "abierto" => array:3 [
    "ES" => true
    "ES2" => true
    "LATM" => true
  ]
  "gratuito" => true
  "lecturas" => array:2 [
    "total" => 4383
    "formatos" => array:3 [
      "EPUB" => 290
      "HTML" => 3457
      "PDF" => 636
    ]
  ]
  "Traduccion" => array:1 [
    "es" => array:17 [
      "pii" => "X0211699508033080"
      "issn" => "02116995"
      "doi" => " "
      "estado" => "S300"
      "fechaPublicacion" => "2008-04-01"
      "documento" => "article"
      "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/"
      "subdocumento" => "fla"
      "cita" => "Nefrologia. 2008;28:123-8"
      "abierto" => array:3 [
        "ES" => true
        "ES2" => true
        "LATM" => true
      ]
      "gratuito" => true
      "lecturas" => array:2 [
        "total" => 12670
        "formatos" => array:3 [
          "EPUB" => 298
          "HTML" => 11266
          "PDF" => 1106
        ]
      ]
      "es" => array:10 [
        "idiomaDefecto" => true
        "titulo" => "Diferencias en la función de los péptidos paratiroideos. ¿Qué estamos midiendo?"
        "tienePdf" => "es"
        "tieneTextoCompleto" => "es"
        "paginas" => array:1 [
          0 => array:2 [
            "paginaInicial" => "123"
            "paginaFinal" => "128"
          ]
        ]
        "titulosAlternativos" => array:1 [
          "en" => array:1 [
            "titulo" => "Differences in the function of parathyroid peptides. What are we measuring?"
          ]
        ]
        "contieneTextoCompleto" => array:1 [
          "es" => true
        ]
        "contienePdf" => array:1 [
          "es" => true
        ]
        "resumenGrafico" => array:2 [
          "original" => 0
          "multimedia" => array:7 [
            "identificador" => "fig1"
            "etiqueta" => "Fig. 1"
            "tipo" => "MULTIMEDIAFIGURA"
            "mostrarFloat" => true
            "mostrarDisplay" => false
            "copyright" => "Elsevier España"
            "figura" => array:1 [
              0 => array:4 [
                "imagen" => "491527_figura1.jpg"
                "Alto" => 508
                "Ancho" => 633
                "Tamanyo" => 54853
              ]
            ]
          ]
        ]
        "autores" => array:1 [
          0 => array:2 [
            "autoresLista" => "Concepción de La Piedra, E. Fernández, M.ª L. González Casaus, E. González Parra"
            "autores" => array:4 [
              0 => array:2 [
                "nombre" => "Concepción"
                "apellidos" => "de La Piedra"
              ]
              1 => array:2 [
                "Iniciales" => "E."
                "apellidos" => "Fernández"
              ]
              2 => array:2 [
                "nombre" => "M.ª L."
                "apellidos" => "González Casaus"
              ]
              3 => array:2 [
                "Iniciales" => "E."
                "apellidos" => "González Parra"
              ]
            ]
          ]
        ]
      ]
      "idiomaDefecto" => "es"
      "Traduccion" => array:1 [
        "en" => array:9 [
          "pii" => "X2013251408033088"
          "doi" => " "
          "estado" => "S300"
          "subdocumento" => ""
          "abierto" => array:3 [
            "ES" => true
            "ES2" => true
            "LATM" => true
          ]
          "gratuito" => true
          "lecturas" => array:1 [
            "total" => 0
          ]
          "idiomaDefecto" => "en"
          "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X2013251408033088?idApp=UINPBA000064"
        ]
      ]
      "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0211699508033080?idApp=UINPBA000064"
      "url" => "/02116995/0000002800000002/v0_201502091346/X0211699508033080/v0_201502091346/es/main.assets"
    ]
  ]
  "itemSiguiente" => array:17 [
    "pii" => "X201325140803307X"
    "issn" => "20132514"
    "doi" => " "
    "estado" => "S300"
    "fechaPublicacion" => "2008-04-01"
    "documento" => "article"
    "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/"
    "subdocumento" => "fla"
    "cita" => "Nefrologia (English Version). 2008;28:129-34"
    "abierto" => array:3 [
      "ES" => true
      "ES2" => true
      "LATM" => true
    ]
    "gratuito" => true
    "lecturas" => array:2 [
      "total" => 3604
      "formatos" => array:3 [
        "EPUB" => 264
        "HTML" => 2849
        "PDF" => 491
      ]
    ]
    "en" => array:9 [
      "idiomaDefecto" => true
      "titulo" => "Should we consider the cost-effectiveness of the different therapies when applying the recommendations on phosphorus-chelating agents?"
      "tienePdf" => "en"
      "tieneTextoCompleto" => "en"
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "129"
          "paginaFinal" => "134"
        ]
      ]
      "titulosAlternativos" => array:1 [
        "es" => array:1 [
          "titulo" => "¿Debemos considerar el costo-efectividad de los distintos tratamientos al aplicar las recomendaciones sobre los captores (quelantes) de fósforo?"
        ]
      ]
      "contieneTextoCompleto" => array:1 [
        "en" => true
      ]
      "contienePdf" => array:1 [
        "en" => true
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "Ángel Luis Martín de Francisco"
          "autores" => array:1 [
            0 => array:2 [
              "nombre" => "Ángel Luis"
              "apellidos" => "Martín de Francisco"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "en"
    "Traduccion" => array:1 [
      "es" => array:9 [
        "pii" => "X0211699508033072"
        "doi" => " "
        "estado" => "S300"
        "subdocumento" => ""
        "abierto" => array:3 [
          "ES" => true
          "ES2" => true
          "LATM" => true
        ]
        "gratuito" => true
        "lecturas" => array:1 [
          "total" => 0
        ]
        "idiomaDefecto" => "es"
        "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0211699508033072?idApp=UINPBA000064"
      ]
    ]
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X201325140803307X?idApp=UINPBA000064"
    "url" => "/20132514/0000002800000002/v0_201502091614/X201325140803307X/v0_201502091614/en/main.assets"
  ]
  "en" => array:10 [
    "idiomaDefecto" => true
    "titulo" => "Differences in the function of parathyroid peptides. What are we measuring?"
    "tieneTextoCompleto" => true
    "paginas" => array:1 [
      0 => array:2 [
        "paginaInicial" => "123"
        "paginaFinal" => "128"
      ]
    ]
    "autores" => array:1 [
      0 => array:3 [
        "autoresLista" => "Concepción de La Piedra, E. Fernández, M.ª L. González Casaus, E. González Parra"
        "autores" => array:4 [
          0 => array:4 [
            "nombre" => "Concepción"
            "apellidos" => "de La Piedra"
            "email" => array:1 [
              0 => "cpiedra@fjd.es"
            ]
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">a</span>"
                "identificador" => "affa"
              ]
            ]
          ]
          1 => array:3 [
            "Iniciales" => "E."
            "apellidos" => "Fern&#225;ndez"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">b</span>"
                "identificador" => "affb"
              ]
            ]
          ]
          2 => array:3 [
            "nombre" => "M&#46;&#170; L&#46;"
            "apellidos" => "Gonz&#225;lez Casaus"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">c</span>"
                "identificador" => "affc"
              ]
            ]
          ]
          3 => array:3 [
            "Iniciales" => "E."
            "apellidos" => "Gonz&#225;lez Parra"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">d</span>"
                "identificador" => "affd"
              ]
            ]
          ]
        ]
        "afiliaciones" => array:4 [
          0 => array:3 [
            "entidad" => "Servicio de Bioquímica, Fundación Jiménez Díaz, Madrid, Madrid,  "
            "etiqueta" => "<span class="elsevierStyleSup">a</span>"
            "identificador" => "affa"
          ]
          1 => array:3 [
            "entidad" => "Servicio de Nefrología, Hospital Arnau Vilanova, Lérida, Lérida, España, "
            "etiqueta" => "<span class="elsevierStyleSup">b</span>"
            "identificador" => "affb"
          ]
          2 => array:3 [
            "entidad" => "Servicio de Bioquímica, Hospital Central Gómez Ulla, Madrid, Madrid, España, "
            "etiqueta" => "<span class="elsevierStyleSup">c</span>"
            "identificador" => "affc"
          ]
          3 => array:3 [
            "entidad" => "Servicio de Nefrologí, Hospital Central Gómez Ulla, Madrid, Madrid, España, "
            "etiqueta" => "<span class="elsevierStyleSup">d</span>"
            "identificador" => "affd"
          ]
        ]
      ]
    ]
    "titulosAlternativos" => array:1 [
      "es" => array:1 [
        "titulo" => "Diferencias en la funci&#243;n de los p&#233;ptidos paratiroideos&#46; &#191;Qu&#233; estamos midiendo&#63;"
      ]
    ]
    "textoCompleto" => "<p class="elsevierStylePara">Acentury went by since the anatomical discovery of the parathyroid gland in 1825 until Collip demonstrated that the administration of the parathyroid hormone &#40;PTH&#41; prevented tetany and normalized plasma calcium levels&#46;<span class="elsevierStyleSup">1&#44;2</span> In a more rapid way&#44; within the last two decades the molecular mechanisms have been known as well as many other factors that act in a coordinated way at the parathyroid gland in order to regulate serum calcium levels&#46; The identification and cloning of receptors for PTH&#44; calcium and vitamin D&#44; as well as the knowledge on the related hereditary disorders have allowed advancing in the knowledge on this complicated network&#46; Is has also become evident that phosphorus plays a key role in PTH regulation&#44; although we still do not know the existence of specific receptors for it at the thyroid gland&#46;<span class="elsevierStyleSup">3</span> Recently&#44; the studies carried out in knockout mice have allowed knowing the connections between the fibroblast growth factor &#40;FGF 23&#41; and phosphorus&#44; vitamin D&#44; and PTH&#46;<span class="elsevierStyleSup">4</span> Finally&#44; as another piece in this complex puzzle&#44; there are recent evidences pointing out that PTH fragments may play an antagonistic role of the intact molecule&#44; exerting thus a hypocalcaemic function&#46;</p><p class="elsevierStylePara">There are several circulating parathyroid peptides with different functions and they even act through different receptors&#46; Figure 1a shows a scheme of the different circulating PTH fragments known so far&#58;</p><p class="elsevierStylePara">&#191; Intact PTH &#40;PTH 1-84&#41; is compounded by a peptide of 84 amino acids &#40;AA&#41;&#44; obtained by consecutive proteolysis of two larger peptides of 115 AA and 90 AA&#44; respectively&#46;</p><p class="elsevierStylePara">&#191; All carboxi-terminal fragments bear the C-terminal portion and lack a series of AA at the N-terminal position&#46; They are categorized into two groups&#58;</p><p class="elsevierStylePara">1&#46; The larger ones&#44; &#171;N-truncated&#187;&#44; have lost a series of AA at any place of the segment comprised between AA 1 to 34&#46; Their existence has been discovered within the last 5 years<span class="elsevierStyleSup">5</span> and have been named &#171;PTH not 1-84&#187; &#40;fig&#46; 1a&#41;&#46;</p><p class="elsevierStylePara">2&#46; There is another group of C-terminal fragments&#58; these are lacking a segment beyond AA 34 and their N structure begins at positions 34&#44; 37&#44; 41&#44; and 43&#46; These fragments are classically named &#171;C-terminal&#187; &#40;fig&#46; 1a&#41;&#46;</p><p class="elsevierStylePara">&#191; Another recently discovered fragment is termed &#171;amino PTH&#187; and has got an AA sequence similar to that of the intact molecule &#40;1-84&#41;&#44; although it presents a phosphorylation at AA 17&#46;<span class="elsevierStyleSup">6</span> Its function is unknown&#46; It has recently been observed that it is present in higher proportions among patients with parathyroid carcinoma and among patients with primary and secondary severe hyperparathyroidism&#46;<span class="elsevierStyleSup">7</span></p><p class="elsevierStylePara">Given that the C-terminal fragments are biologically active and act through different receptors&#44; some authors have proposed the term &#171;parathyroid polyhormone&#187;&#46;<span class="elsevierStyleSup">8</span> These parathyroid peptides have different actions and regulation mechanisms and metabolism&#46;</p><p class="elsevierStylePara">Intact PTH or the 1-84 fragment account for the classical functions on the bone and kidney and on the &#171;vitamin D-1-alpha-hydroxilase&#187; enzyme&#44; inducing the synthesis of calcitriol&#46; All of these actions share a common objective&#58; to raise plasma calcium levels&#46; Within the parathyroid gland&#44; the Calcium-sensing receptor &#40;CaSR&#41;<span class="elsevierStyleSup">9</span> is directly implicated in the mechanism responsible for the modulation of parathyroid hormone release depending on the extracellular calcium level&#46; Thus&#44; during hypocalcaemic conditions&#44; PTH synthesis and release are stimulated&#46; Hyperphosphatemia is another potent stimulating factor for PTH synthesis and release&#46; By contrast&#44; calcitriol&#44; through its receptor &#40;VDR&#41;&#44; has an inhibitory effect&#46; The classical actions of PTH 1-84 are mediated through a common PTH receptor &#40;PTHR1&#41; and PTH-related protein &#40;PTH rP&#41;&#44; which is present in many tissues&#46; The amino-terminal sequence&#44; constituted by the first 34 AA &#40;N-terminal structure&#41;&#44; is necessary for its action&#46; The interaction between the amino terminal portion with the PTHR1 receptor activates the protein kinase A and C pathways at target tissues&#46;</p><p class="elsevierStylePara">In experimental studies&#44; it has been observed that the fragments termed &#171;no-1-84&#187;&#44; among which the most abundant one is fragment 7-84&#44; have antagonistic biological effects to those of the intact molecule&#46; Indeed&#44; they have hypocalcaemic&#44; hyperphosphatemic&#44; and hypophosphaturic effects&#46; On the other hand&#44; they counteract the hypercalcaemic effect of PTH &#40;1-34&#41; and of PTH &#40;1-84&#41;&#46; Besides&#44; they inhibit vitamin D-induced osteoclastogenesis&#46;<span class="elsevierStyleSup">10</span> All the carboxi-terminal-type fragments of the PTH molecule bind to a new type of receptor of the hormone in bone cells &#40;CPTHR&#41;&#44; which is different from the PTHR1 receptor that requires the 1-34 amino terminal portion of intact PTH to get activated&#46;<span class="elsevierStyleSup">11</span></p><p class="elsevierStylePara">In vivo studies have been carried out in parathyroidectomized rats&#46; The administration of PTH 7-84 decreases serum calcium and phosphate levels and inhibits PTH 1-84-induced phosphaturia&#44; suggesting that it promotes calcium and phosphate entry into the bone&#46;<span class="elsevierStyleSup">11</span> Slatopolsky et al&#46;<span class="elsevierStyleSup">12</span> showed that thyro-parathyroidectomized rats become hypercalcaemic when they are administered PTH 1-84 and the 1-34 fragment &#40;Teriparatide&#41;&#44; and that simultaneous administration of PTH 7-84 blocks this effect and induces hypocalcaemia&#46; They also showed that the administration of PTH 7-84 is accompanied by a decrease in the number of osteoclasts and osteoblasts and that PTH 1-84-induced bone formation is abrogated when PTH 7-84 is administered simultaneously&#44; thus seeming that the differences induced in serum calcium levels are due to a direct effect on the bone&#46; The authors propose the interesting hypothesis that accumulation of these fragments during uremia may be responsible in part of skeletal resistance to PTH&#46;<span class="elsevierStyleSup">12</span></p><p class="elsevierStylePara">The actions of the carboxi-terminal fragments &#40;including the &#171;not 1-84&#187;&#41; have not yet been identified under physiological or pathological conditions&#46; It is likely that the biological effect may be more relevant during renal failure since they might reach higher circulating levels&#46; It has experimentally been shown that under acute hypocalcaemic conditions&#44; PTH 1-84 excretion is favored over that of carboxi-terminal fragments&#44; and that the induction of acute hypercalcaemia reverses the ratio&#46; Under chronic hypocalcaemia conditions&#44; the higher the amount of PTH needed to maintain the calcium level &#40;for instance&#44; in chronic renal failure with vitamin D deficiency&#41;&#44; the higher the amount of PTH 1-84 is secreted at any calcium level and the lower the carboxi-terminal fragments are&#46; It happens the same way in the opposite situation&#46; The lower the amount of PTH needed &#40;for instance&#44; in vitamin D-induced hypercalcaemia&#41;&#44; the lower the amount of PTH 1-84 is secreted and the higher the carboxi-terminal fragments are&#46;<span class="elsevierStyleSup">10</span> Therefore&#44; given that the changes in serum calcium levels regulate the PTH 1-84&#47;C-PTH ratio&#44; secreted at the parathyroid glands&#44; it seems logical to deduce that the carboxi-terminal fragments must have some physiological role&#46;<span class="elsevierStyleSup">13&#44; 14</span></p><p class="elsevierStylePara">Carboxi-terminal fragments act through a receptor &#40;CPTHR&#41; other than PTHR1&#44; which has not being well defined or cloned yet&#46; It has been shown to be present on the cytoplasmic membrane of chicken renal cells&#44; rat osteosarcoma cells&#44; and osteocyte-like cells of mouse bone&#46; These PTH R1-deficient cells have been used to show the affinity of carboxiterminal fragments for this receptor&#46; To date&#44; there are no data in vivo showing the existence of such receptor&#46;<span class="elsevierStyleSup">15&#44; 16</span></p><p class="elsevierStylePara">The regulation and metabolism of the different fragments condition their plasma levels&#46; In healthy individuals&#44; the amount of circulating C-PTH is very much higher &#40;80&#37;&#41; than that of the intact molecule &#40;20&#37;&#41;&#46; This disproportion is likely justified by the shorter half-life of the latter &#40;5-8 minutes&#41;&#46; The carboxi-terminal fragments are cleared by the kidney and accumulate when there is a decreased in glomerular filtration rate&#46; So that in renal failure this type of fragments&#44; which proportion is of 95&#37;&#44; accumulates&#46;<span class="elsevierStyleSup">14</span> Figure 2 shows the different proportions of circulating PTH fragments in healthy individuals and in renal failure&#46;</p><p class="elsevierStylePara">The release and metabolism of the different PTH fragments is illustrated in an integrated way in figure 3&#46; The parathyroid gland releases PTH 1-84 and C-PTH fragments in amounts proportional to serum calcium levels&#46; Under hypocalcaemia the proportion of PTH 1-84 released is higher&#44; and by contrast hypocalcaemia increases the amount of released C-PTH fragments&#46; All of them exert their effect on the bone by interacting with their specific receptors &#40;PTHR1 o CPTHR&#41; or are cleared by the kidney or the liver&#46; PTH 1-84 is rapidly degraded by liver Kupffer cells into a series of carboxi-terminal fragments identical to those secreted by the parathyroid gland&#44; which re-enter into the bloodstream&#46;<span class="elsevierStyleSup">13</span></p><p class="elsevierStylePara">Given that the existence of many of these PTH fragments was unknown until relatively recent dates&#44; the available assays for quantifying PTH 1-84 presented&#44; and still present&#44; crossed values with other parathyroid peptides&#46; This fact may represent an important clinical problem when assessing the situation of the levels of this hormone for establishing a therapy&#44; especially in the case of patients with chronic renal disease&#46;</p><p class="elsevierStylePara">The first determinations of serum PTH levels were carried out by radio-immune analysis &#40;RIA&#41; around the year 1980&#46; These assays were mounted at the same laboratories where the antibodies were generated and the hormone was labeled with <span class="elsevierStyleSup">125</span>I&#46;</p><p class="elsevierStylePara">In the assay an anti-PTH antibody was used detecting different fragments of the hormone depending on the site of it being recognized&#46; Thus&#44; there were radio-immune analyses for amino-terminal&#44; intermediate&#44; and carboxi-terminal PTH fragments&#46; The carboxi-terminal fragments were the ones most commonly used&#44; although as shown in figure 1b&#44; all circulating PTH fragments besides PTH 1-84 were assessed&#44; so that the true value of physiologically active &#40;&#171;intact&#187;&#41; PTH were highly overestimated&#44; especially in patients with renal failure in whom the proportion of circulating C-terminal fragments was much higher than in subjects with normal renal function&#46;</p><p class="elsevierStylePara">This situation was improved at the laboratories because kits for PTH determination started to be commercially available&#44; so that there was no need for labeling the hormone or creating the antibodies to carry out the determination&#44; although the problem of levels overestimation still was the same&#46; These assays have been called first generation assays &#40;fig&#46; 1b&#41;&#46;</p><p class="elsevierStylePara">An important change occurred in 1987<span class="elsevierStyleSup">17</span> when the Nichols Institute Diagnostic Inc developed an immune-radiometric assay &#40;IRMA&#41; to detect PTH&#44; the first of the so-called analysis of &#171;intact PTH&#187;&#46; The assay used two antibodies&#58; one directed against the amino-terminal region &#40;1-34 epitope&#41; and the other one against the carboxi-terminal region &#40;39-84&#41;&#46; In order to be determined&#44; a fragment has to simultaneously bind to both antibodies&#46; Since at that time the existence of the &#171;not 1-84&#187; PTH fragments was unknown&#44; which have been discovered more recently&#44; 5 as well as of the &#171;amino-PTH&#187; fragment&#44; 6 the general believe was that only intact PTH 1-84 values were being determined&#44; and thus of the physiologically active hormone&#46;</p><p class="elsevierStylePara">In theory&#44; the assay was so perfect that from the several studies performed comparing histomorphometry with PTH levels determined by means of Nichols&#191;IRMA<span class="elsevierStyleSup">18-20</span> the &#171;National Kidney Foundation&#47;Kidney-Dialysis Outcomes Quality Initiative &#40;NKF&#47;K-DOQI&#41;&#187; guidelines were elaborated<span class="elsevierStyleSup">21</span> recommending to maintain PTH levels in patients with renal osteodystrophy between 150 and 300 ng&#47;L&#46;</p><p class="elsevierStylePara">Figure 1c shows all the PTH fragments detected by IRMAs called &#171;intact PTH&#187;&#46; As it may be observed&#44; in addition to PTH 1-84 the &#171;not 1-84&#187; fragments and &#171;amino-PTH&#187; are also detected&#44; excluding only from the determination the Cterminal PTH fragments&#46;</p><p class="elsevierStylePara">Several commercial firms developed their own IRMA-type or electrochemiluminescent kits of the so-called &#171;intact-PTH&#187;&#46; Generally all of them use antibodies directed against the same epitopes as the one used by Nichols&#44; with the exception of the assay by Roche called Elecsys&#44; which uses antibodies against the PTH regions 26-32 and 55-64 and which is the only one not detecting the amino-PTH fragment but yes all the &#171;not 1-84&#187; fragments&#44; similar to the other assays of the like from other commercial firms&#46; These assays have been termed 2d generation assays &#40;fig&#46; 1c&#41;&#46;</p><p class="elsevierStylePara">Since the discovery of &#171;not 1-84&#187; PTH fragments&#44; the manufacturer Nichols &#40;that is no longer in the market&#41; and other manufacturers such as Scantibodies&#44; developed new methods with two antibodies in which they still used the antibody directed against the classical carboxi-terminal region and a new one directed against the 4-5 first AA within the amino-terminal region of the PTH molecule&#44; so that most of &#171;not 1-84&#187; fragments were no longer detected&#44; although the &#171;amino-terminal &#187; fragment was still recognized&#46; Figure 1d shows the fragments detected by this type of assays&#44; which have been termed third generation assays&#44; or of &#171;bio-PTH&#187; detection or &#171;whole PTH&#187; detection&#46; As it may be easily deduced&#44; the sample analysis by means of a third generation assay offers much lower values than the use of a second generation assay since not all &#171;not 1-84&#187; fragments are being detected&#46; Its determination has not become generalized in clinical practice because it is a technically demanding method&#46; Another limitation to translate it into the clinical practice is that there are no studies correlating its values with bone histopathology in chronic renal disease&#44; by contrast with &#171;intact PTH&#187;&#46;<span class="elsevierStyleSup">22&#44; 23</span> On the other hand&#44; the fact that &#171;bio-PTH&#187; and &#171;Intact PTH&#187; levels closely correlate has prevented the widespread use of the former&#46; Some authors proposed that the PTH 1-84&#47;&#187;whole&#187; PTH ratio could be useful in the differential diagnosis between low and high bone turnover&#44; although the studies carried out in short patient series have not met the expectancies&#46;<span class="elsevierStyleSup">24&#44; 25</span></p><p class="elsevierStylePara">In this way&#44; in the case that quantification of bio-PTH or whole PTH is not feasible in routine clinical practice&#44; we should be aware that the PTH levels provided by the laboratory have been quantified by means of a second generation assay and thus it corresponds to the sum of PTH 1-84 and &#171;not 1-84&#187; PTH &#40;and in some cases also of amino-PTH&#44; which is the minority&#41;&#44; which are parathyroid peptides with antagonistic effects&#46;</p><p class="elsevierStylePara">In addition to this serious problem of overestimation of the true PTH 1-84 value&#44; there is another problem further complicating the use of the results from these assays by the clinicians&#58; the lack of homogeneous calibration of the determinations between the different manufacturers&#46; Since they do not use the same PTH standards&#44; the numerical results with the same sample may significantly vary with the different techniques used&#44; so that the reference interval of &#171;150-300 ng&#47;L&#187; proposed by the K&#47;DOQI guidelines is no longer valid&#46; JC Souberbielle et al&#46;<span class="elsevierStyleSup">22</span> have confirmed this in an excellent work published in 2006&#46;</p><p class="elsevierStylePara">This inter-method variability makes that&#44; depending on the method used&#44; there is a different percentage of patients requiring pharmacological treatment or even parathyroidectomy&#44; provided that we assume that the values from our laboratory correspond to those used in the K&#47;DOQI guidelines&#46; This methodological error implies inappropriate clinical decision-making&#44; which entails repercussions on health and a considerable financial impact due to the excessive prices of the drugs used for treating hyperparathyroidism&#46;<span class="elsevierStyleSup">26</span></p><p class="elsevierStylePara">Given all this&#44; under the auspices of the Spanish Society of Nephrology&#44; the PTH Measurement Working Group comprised by experts on mineral metabolism and on clinical analyses&#44; has carried out a survey among the Spanish Nephrology Departments in order to know the methods used in our country&#46; Given the existence of high variability &#40;fig&#46; 4&#41;&#44; this Group also considered calculating the inter-method variability in order to provide nephrologists with the appropriate correction factors that should be applied to obtain the same values as with the use of Allegro intact PTH by Nichols &#40;that is the one used for the K&#47;DOQI reference ranges&#41; and with the &#171;bio PTH&#187; by Scantibodies&#46; Although this work is still on going&#44; we already have available the preliminary results that we present since they may be useful in clinical practice&#46; Table 1 shows the results obtained when analyzing PTH levels in 150 hemodialysis patients in whom PTH was simultaneously determined at the laboratories of the Fundaci&#243;n Jim&#233;nez D&#237;az Hospital&#44; La Paz Hospital&#44; and G&#243;mez Ulla Hospital&#44; by means of the six most commonly used methods in our country&#46; It is striking the high inter-method variability that makes K&#47;DOQI references invalid&#46; We&#44; the nephrologists&#44; should from now on be informed of the method applied by our reference laboratory in order to apply the corresponding correction factors&#46; This will allow the clinicians to keep on using the same references and guidelines until there will exist other valid alternatives&#46; <br></br></p>"
    "pdfFichero" => "P-E-S-A491-EN.pdf"
    "tienePdf" => true
    "bibliografia" => array:2 [
      "titulo" => "Bibliography"
      "seccion" => array:1 [
        0 => array:1 [
          "bibliografiaReferencia" => array:26 [
            0 => array:3 [
              "identificador" => "bib1"
              "etiqueta" => "1"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Díez Pérez A, Puig Manresa J,Martínez Izquierdo MT, Nogués Solan X, Vivancos Lleida J. Hiperparatiroidismo primario. En: Patología ósea metabólica. Ed: S Serrano, J Aubia y ML Mariñoso. Sandoz SAE; Barcelona, 1990."
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            1 => array:3 [
              "identificador" => "bib2"
              "etiqueta" => "2"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Collip JB. The extraction of a parathyroid hormone which will prevent or control parathyroid tetany and which regualtes the level of blood calcium. J Biol Chem 1925; 63: 395-438."
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            2 => array:3 [
              "identificador" => "bib3"
              "etiqueta" => "3"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Rodríguez M, Nemeth E, Martin. The calcium-sensing receptor: a key factor in the pathogenesis of secondary hyperparathyroidism. Am J Physiol Renal Physiol 2005; 288: F253-64. <a href="http://www.ncbi.nlm.nih.gov/pubmed/15507543" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            3 => array:3 [
              "identificador" => "bib4"
              "etiqueta" => "4"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Stubbs J, Liu S, Quarles LD. Role of fibroblast growth factor 23 in phosphate homeostasis and pathogenesis of disordered mineral metabolism in chronic kidney disease. Semin Dial 2007; 20: 302-8. <a href="http://www.ncbi.nlm.nih.gov/pubmed/17635819" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            4 => array:3 [
              "identificador" => "bib5"
              "etiqueta" => "5"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "D¿Amour P, Brossard JH, Rousseau L y cols. Structure of non-(1-84) PTH fragments secreted by parathyroid glands in primary and secondary hyperparathyroidism. Kidney Int 2005; 68: 998-1007. <a href="http://www.ncbi.nlm.nih.gov/pubmed/16105030" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            5 => array:3 [
              "identificador" => "bib6"
              "etiqueta" => "6"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "D¿Amour P, Brossard JH, Rousseau L y cols. Amino-terminal form of parathyroid hormone (PTH) with immunologic similarities to hPTH (1-84) is overproduced in primary and secondry hyperparathyroidism. Clin Chem 2003; 49: 2037-2044. <a href="http://www.ncbi.nlm.nih.gov/pubmed/14633875" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            6 => array:3 [
              "identificador" => "bib7"
              "etiqueta" => "7"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "D¿Amour P. Circulating PTH molecular forms: What we know and what we don¿t. Kidney Int 2006; 70: S29-S33."
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            7 => array:3 [
              "identificador" => "bib8"
              "etiqueta" => "8"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Nemeth EF. The parathyroid polyhormone hypotesis revisited. Kidney Int 2006; 70: 522."
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            8 => array:3 [
              "identificador" => "bib9"
              "etiqueta" => "9"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Brown EM, Gamba G, Riccardi D y cols. Cloning and characterization of an extracellular Ca2 -sensing receptor from bovine parathyroid. Nature 1993; 366: 575-580. <a href="http://www.ncbi.nlm.nih.gov/pubmed/8255296" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            9 => array:3 [
              "identificador" => "bib10"
              "etiqueta" => "10"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Nguyen-Yamamoto L, Rousseau L, Brossard JH y cols. Synthetic carboxyl- terminal fragments of PTH decrease ionized calcium concentration in rats by acting on a receptor different from the PTH/PTHrP receptor. Endocrinology 2001; 142: 136-139."
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            10 => array:3 [
              "identificador" => "bib11"
              "etiqueta" => "11"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Divieti P, John MR, Juppner H, Bringhurst FR. Human PTH-(7-84) inhibits bone resorption in vitro via actions independent of the type 1 PTH/PTHrP receptor. Endocrinology 2002; 143: 171-176. <a href="http://www.ncbi.nlm.nih.gov/pubmed/11751606" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            11 => array:3 [
              "identificador" => "bib12"
              "etiqueta" => "12"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Slatopolsky E, Finch E, Clay P, Martin D, Sicard G, Singer G, Gao P, Cantor T, Dusso A. A novel mechanism for skeletal resistance in uremia. Kidney Int 2000; 58: 753-761. <a href="http://www.ncbi.nlm.nih.gov/pubmed/10916099" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            12 => array:3 [
              "identificador" => "bib13"
              "etiqueta" => "13"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Murray TM, Rao LG, Divieti P, Bringhurst FR. Parathyroid Hormone Secretion and Action: Evidencefor Discrete Receptors for the Carboxyl- Terminal Region and Related Biological Actions of Carboxyl-Terminal Ligands. Endocrine Rev 2005; 26 (1): 78-113."
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            13 => array:3 [
              "identificador" => "bib14"
              "etiqueta" => "14"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Ureña Torres P. The need for reliable serum parathyroid hormone measurements. Kidney Int 2006; 70: 240-243. <a href="http://www.ncbi.nlm.nih.gov/pubmed/16838038" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            14 => array:3 [
              "identificador" => "bib15"
              "etiqueta" => "15"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Nguyen-Yamamoto L, Rousseau L, Brossard JH y cols. Synthetic carboxyl- terminal fragments of PTH decrease ionized calcium concentration in rats by acting on a receptor different from the PTH/PTHrP receptor. Endocrinology 2001; 142: 136-139."
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            15 => array:3 [
              "identificador" => "bib16"
              "etiqueta" => "16"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Dieveti P, Geller AL, Suliman G. Receptors Specific for the Carboxyl- Terminal Region of Parathyroid Hormone on Bone-Derived Cells: determinants of Ligand Binding and Bioactivity. Endocrinology 2005; 146: 1863-1870."
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            16 => array:3 [
              "identificador" => "bib17"
              "etiqueta" => "17"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Nussbaum S, Zahradnik R, Lavigne J y cols. Highly sensitive two-site immunoradiometric assay of parathyrin, and its clinical utility in evaluating patients wth hypercalcemia. Clin Chem 1987; 33: 1364-1367. <a href="http://www.ncbi.nlm.nih.gov/pubmed/3608153" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            17 => array:3 [
              "identificador" => "bib18"
              "etiqueta" => "18"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Sherrard DJ, Hercz G, Pei Y y cols. The spectrum of bone disease in endstage renal failure- an evolving disorder. Kidney Int 1993; 43: 436-442. <a href="http://www.ncbi.nlm.nih.gov/pubmed/8441240" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            18 => array:3 [
              "identificador" => "bib19"
              "etiqueta" => "19"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Hercz G, Pei Y, Geenwood y cols. Aplastic osteodistrophy without aluminium: the role of «supressed» parathyroid function. Kidney Int 1993; 44: 860-866. <a href="http://www.ncbi.nlm.nih.gov/pubmed/8258962" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            19 => array:3 [
              "identificador" => "bib20"
              "etiqueta" => "20"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Wang M, Hercz G, Sherrard D y cols. Relationship between intact 1- 84 parathyroid hormone and bone histomorphometric parameters in dialysis patients without aluminium toxicity. Am J Kidney Dis 1995; 26: 836-844. <a href="http://www.ncbi.nlm.nih.gov/pubmed/7485142" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            20 => array:3 [
              "identificador" => "bib21"
              "etiqueta" => "21"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "K/DOQI guidelines for the management of renal osteodistrophy. Am J Kidney Dis 2003; 42 (Supl. 3): S1-S201. <a href="http://www.ncbi.nlm.nih.gov/pubmed/14520607" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            21 => array:3 [
              "identificador" => "bib22"
              "etiqueta" => "22"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Souberbielle JC, Boutten A, Carlier MC y cols. Inter-mehod variability in PTH measurement: implication in the care of CKD patients. Kidney Int 2006; 70: 345-350. <a href="http://www.ncbi.nlm.nih.gov/pubmed/16788691" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            22 => array:3 [
              "identificador" => "bib23"
              "etiqueta" => "23"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Torres A, Lorenzo V, Hernández D, Rodríguez JC, Concepción MT, Rodríguez AP, Hernández A, De Bonis E, Darias E, González-Posada JM, Losada M, Rufino M, Felsenfeld AJ, Rodríguez M. Bone disease in predialysis, hemodialysis and CAPD patients: evidence of a better bone response to PTH. Kidney Int 1995; 47: 1434-1442. <a href="http://www.ncbi.nlm.nih.gov/pubmed/7637272" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            23 => array:3 [
              "identificador" => "bib24"
              "etiqueta" => "24"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Coen G, Bonucci E, Ballanti P, Balducci A,Calabria S,Nicolai GA, Fischer MS, Lifrieri F, Manni M, Morosetti M, Moscaritolo E, Sardella D. PTH 1-84 and PTH «7-84» in the noninvasive diagnosis of renal bone disease. Am J Kidney Diseases 2002; 40: 348-354."
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            24 => array:3 [
              "identificador" => "bib25"
              "etiqueta" => "25"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Cantor T, Yang Z, Caraiani N, Ilamathi E. Lack of comparability of intact parathyroid hormone measurements among comercial assays for end-stage renal disease patients: implication for treatment decisions. Clin Chem 2006; 52: 1771-1776. <a href="http://www.ncbi.nlm.nih.gov/pubmed/16858070" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            25 => array:3 [
              "identificador" => "bib26"
              "etiqueta" => "26"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Foley RN, Li S, Liu J, Gilbertson DT, Chen SC, Collins AJ. The fall and rise of parathyroidectomy in US hemodialysis patients, 1992 to 2002. J Am Soc Nephrol 2005; (1): 210-218."
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
          ]
        ]
      ]
    ]
  ]
  "idiomaDefecto" => "en"
  "url" => "/20132514/0000002800000002/v0_201502091614/X2013251408033088/v0_201502091614/en/main.assets"
  "Apartado" => array:4 [
    "identificador" => "35429"
    "tipo" => "SECCION"
    "en" => array:2 [
      "titulo" => "Editorials"
      "idiomaDefecto" => true
    ]
    "idiomaDefecto" => "en"
  ]
  "PDF" => "https://static.elsevier.es/multimedia/20132514/0000002800000002/v0_201502091614/X2013251408033088/v0_201502091614/en/P-E-S-A491-EN.pdf?idApp=UINPBA000064&text.app=https://revistanefrologia.com/"
  "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X2013251408033088?idApp=UINPBA000064"
]
Share
Journal Information

Statistics

Follow this link to access the full text of the article

Differences in the function of parathyroid peptides. What are we measuring?
Diferencias en la función de los péptidos paratiroideos. ¿Qué estamos midiendo?
Concepción de La Piedraa, E.. Fernándezb, M.ª L. González Casausc, E.. González Parrad
a Servicio de Bioquímica, Fundación Jiménez Díaz, Madrid, Madrid,
b Servicio de Nefrología, Hospital Arnau Vilanova, Lérida, Lérida, España,
c Servicio de Bioquímica, Hospital Central Gómez Ulla, Madrid, Madrid, España,
d Servicio de Nefrologí, Hospital Central Gómez Ulla, Madrid, Madrid, España,
Read
9410
Times
was read the article
2537
Total PDF
6873
Total HTML
Share statistics
 array:20 [
  "pii" => "X2013251408033088"
  "issn" => "20132514"
  "doi" => " "
  "estado" => "S300"
  "fechaPublicacion" => "2008-04-01"
  "documento" => "article"
  "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/"
  "subdocumento" => "fla"
  "cita" => "Nefrologia &#40;English Version&#41;. 2008;28:123-8"
  "abierto" => array:3 [
    "ES" => true
    "ES2" => true
    "LATM" => true
  ]
  "gratuito" => true
  "lecturas" => array:2 [
    "total" => 4383
    "formatos" => array:3 [
      "EPUB" => 290
      "HTML" => 3457
      "PDF" => 636
    ]
  ]
  "Traduccion" => array:1 [
    "es" => array:17 [
      "pii" => "X0211699508033080"
      "issn" => "02116995"
      "doi" => " "
      "estado" => "S300"
      "fechaPublicacion" => "2008-04-01"
      "documento" => "article"
      "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/"
      "subdocumento" => "fla"
      "cita" => "Nefrologia. 2008;28:123-8"
      "abierto" => array:3 [
        "ES" => true
        "ES2" => true
        "LATM" => true
      ]
      "gratuito" => true
      "lecturas" => array:2 [
        "total" => 12670
        "formatos" => array:3 [
          "EPUB" => 298
          "HTML" => 11266
          "PDF" => 1106
        ]
      ]
      "es" => array:10 [
        "idiomaDefecto" => true
        "titulo" => "Diferencias en la funci&#243;n de los p&#233;ptidos paratiroideos&#46; &#191;Qu&#233; estamos midiendo&#63;"
        "tienePdf" => "es"
        "tieneTextoCompleto" => "es"
        "paginas" => array:1 [
          0 => array:2 [
            "paginaInicial" => "123"
            "paginaFinal" => "128"
          ]
        ]
        "titulosAlternativos" => array:1 [
          "en" => array:1 [
            "titulo" => "Differences in the function of parathyroid peptides&#46; What are we measuring&#63;"
          ]
        ]
        "contieneTextoCompleto" => array:1 [
          "es" => true
        ]
        "contienePdf" => array:1 [
          "es" => true
        ]
        "resumenGrafico" => array:2 [
          "original" => 0
          "multimedia" => array:7 [
            "identificador" => "fig1"
            "etiqueta" => "Fig. 1"
            "tipo" => "MULTIMEDIAFIGURA"
            "mostrarFloat" => true
            "mostrarDisplay" => false
            "copyright" => "Elsevier Espa&#241;a"
            "figura" => array:1 [
              0 => array:4 [
                "imagen" => "491527_figura1.jpg"
                "Alto" => 508
                "Ancho" => 633
                "Tamanyo" => 54853
              ]
            ]
          ]
        ]
        "autores" => array:1 [
          0 => array:2 [
            "autoresLista" => "Concepci&#243;n de La Piedra, E. Fern&#225;ndez, M&#46;&#170; L&#46; Gonz&#225;lez Casaus, E. Gonz&#225;lez Parra"
            "autores" => array:4 [
              0 => array:2 [
                "nombre" => "Concepci&#243;n"
                "apellidos" => "de La Piedra"
              ]
              1 => array:2 [
                "Iniciales" => "E."
                "apellidos" => "Fern&#225;ndez"
              ]
              2 => array:2 [
                "nombre" => "M&#46;&#170; L&#46;"
                "apellidos" => "Gonz&#225;lez Casaus"
              ]
              3 => array:2 [
                "Iniciales" => "E."
                "apellidos" => "Gonz&#225;lez Parra"
              ]
            ]
          ]
        ]
      ]
      "idiomaDefecto" => "es"
      "Traduccion" => array:1 [
        "en" => array:9 [
          "pii" => "X2013251408033088"
          "doi" => " "
          "estado" => "S300"
          "subdocumento" => ""
          "abierto" => array:3 [
            "ES" => true
            "ES2" => true
            "LATM" => true
          ]
          "gratuito" => true
          "lecturas" => array:1 [
            "total" => 0
          ]
          "idiomaDefecto" => "en"
          "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X2013251408033088?idApp=UINPBA000064"
        ]
      ]
      "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0211699508033080?idApp=UINPBA000064"
      "url" => "/02116995/0000002800000002/v0_201502091346/X0211699508033080/v0_201502091346/es/main.assets"
    ]
  ]
  "itemSiguiente" => array:17 [
    "pii" => "X201325140803307X"
    "issn" => "20132514"
    "doi" => " "
    "estado" => "S300"
    "fechaPublicacion" => "2008-04-01"
    "documento" => "article"
    "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/"
    "subdocumento" => "fla"
    "cita" => "Nefrologia &#40;English Version&#41;. 2008;28:129-34"
    "abierto" => array:3 [
      "ES" => true
      "ES2" => true
      "LATM" => true
    ]
    "gratuito" => true
    "lecturas" => array:2 [
      "total" => 3604
      "formatos" => array:3 [
        "EPUB" => 264
        "HTML" => 2849
        "PDF" => 491
      ]
    ]
    "en" => array:9 [
      "idiomaDefecto" => true
      "titulo" => "Should we consider the cost-effectiveness of the different therapies when applying the recommendations on phosphorus-chelating agents&#63;"
      "tienePdf" => "en"
      "tieneTextoCompleto" => "en"
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "129"
          "paginaFinal" => "134"
        ]
      ]
      "titulosAlternativos" => array:1 [
        "es" => array:1 [
          "titulo" => "&#191;Debemos considerar el costo-efectividad de los distintos tratamientos al aplicar las recomendaciones sobre los captores &#40;quelantes&#41; de f&#243;sforo&#63;"
        ]
      ]
      "contieneTextoCompleto" => array:1 [
        "en" => true
      ]
      "contienePdf" => array:1 [
        "en" => true
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "&#193;ngel Luis Mart&#237;n de Francisco"
          "autores" => array:1 [
            0 => array:2 [
              "nombre" => "&#193;ngel Luis"
              "apellidos" => "Mart&#237;n de Francisco"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "en"
    "Traduccion" => array:1 [
      "es" => array:9 [
        "pii" => "X0211699508033072"
        "doi" => " "
        "estado" => "S300"
        "subdocumento" => ""
        "abierto" => array:3 [
          "ES" => true
          "ES2" => true
          "LATM" => true
        ]
        "gratuito" => true
        "lecturas" => array:1 [
          "total" => 0
        ]
        "idiomaDefecto" => "es"
        "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0211699508033072?idApp=UINPBA000064"
      ]
    ]
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X201325140803307X?idApp=UINPBA000064"
    "url" => "/20132514/0000002800000002/v0_201502091614/X201325140803307X/v0_201502091614/en/main.assets"
  ]
  "en" => array:10 [
    "idiomaDefecto" => true
    "titulo" => "Differences in the function of parathyroid peptides&#46; What are we measuring&#63;"
    "tieneTextoCompleto" => true
    "paginas" => array:1 [
      0 => array:2 [
        "paginaInicial" => "123"
        "paginaFinal" => "128"
      ]
    ]
    "autores" => array:1 [
      0 => array:3 [
        "autoresLista" => "Concepci&#243;n de La Piedra, E. Fern&#225;ndez, M&#46;&#170; L&#46; Gonz&#225;lez Casaus, E. Gonz&#225;lez Parra"
        "autores" => array:4 [
          0 => array:4 [
            "nombre" => "Concepci&#243;n"
            "apellidos" => "de La Piedra"
            "email" => array:1 [
              0 => "cpiedra&#64;fjd&#46;es"
            ]
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">a</span>"
                "identificador" => "affa"
              ]
            ]
          ]
          1 => array:3 [
            "Iniciales" => "E."
            "apellidos" => "Fern&#225;ndez"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">b</span>"
                "identificador" => "affb"
              ]
            ]
          ]
          2 => array:3 [
            "nombre" => "M&#46;&#170; L&#46;"
            "apellidos" => "Gonz&#225;lez Casaus"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">c</span>"
                "identificador" => "affc"
              ]
            ]
          ]
          3 => array:3 [
            "Iniciales" => "E."
            "apellidos" => "Gonz&#225;lez Parra"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">d</span>"
                "identificador" => "affd"
              ]
            ]
          ]
        ]
        "afiliaciones" => array:4 [
          0 => array:3 [
            "entidad" => "Servicio de Bioquímica, Fundación Jiménez Díaz, Madrid, Madrid,  "
            "etiqueta" => "<span class="elsevierStyleSup">a</span>"
            "identificador" => "affa"
          ]
          1 => array:3 [
            "entidad" => "Servicio de Nefrología, Hospital Arnau Vilanova, Lérida, Lérida, España, "
            "etiqueta" => "<span class="elsevierStyleSup">b</span>"
            "identificador" => "affb"
          ]
          2 => array:3 [
            "entidad" => "Servicio de Bioquímica, Hospital Central Gómez Ulla, Madrid, Madrid, España, "
            "etiqueta" => "<span class="elsevierStyleSup">c</span>"
            "identificador" => "affc"
          ]
          3 => array:3 [
            "entidad" => "Servicio de Nefrologí, Hospital Central Gómez Ulla, Madrid, Madrid, España, "
            "etiqueta" => "<span class="elsevierStyleSup">d</span>"
            "identificador" => "affd"
          ]
        ]
      ]
    ]
    "titulosAlternativos" => array:1 [
      "es" => array:1 [
        "titulo" => "Diferencias en la funci&#243;n de los p&#233;ptidos paratiroideos&#46; &#191;Qu&#233; estamos midiendo&#63;"
      ]
    ]
    "textoCompleto" => "<p class="elsevierStylePara">Acentury went by since the anatomical discovery of the parathyroid gland in 1825 until Collip demonstrated that the administration of the parathyroid hormone &#40;PTH&#41; prevented tetany and normalized plasma calcium levels&#46;<span class="elsevierStyleSup">1&#44;2</span> In a more rapid way&#44; within the last two decades the molecular mechanisms have been known as well as many other factors that act in a coordinated way at the parathyroid gland in order to regulate serum calcium levels&#46; The identification and cloning of receptors for PTH&#44; calcium and vitamin D&#44; as well as the knowledge on the related hereditary disorders have allowed advancing in the knowledge on this complicated network&#46; Is has also become evident that phosphorus plays a key role in PTH regulation&#44; although we still do not know the existence of specific receptors for it at the thyroid gland&#46;<span class="elsevierStyleSup">3</span> Recently&#44; the studies carried out in knockout mice have allowed knowing the connections between the fibroblast growth factor &#40;FGF 23&#41; and phosphorus&#44; vitamin D&#44; and PTH&#46;<span class="elsevierStyleSup">4</span> Finally&#44; as another piece in this complex puzzle&#44; there are recent evidences pointing out that PTH fragments may play an antagonistic role of the intact molecule&#44; exerting thus a hypocalcaemic function&#46;</p><p class="elsevierStylePara">There are several circulating parathyroid peptides with different functions and they even act through different receptors&#46; Figure 1a shows a scheme of the different circulating PTH fragments known so far&#58;</p><p class="elsevierStylePara">&#191; Intact PTH &#40;PTH 1-84&#41; is compounded by a peptide of 84 amino acids &#40;AA&#41;&#44; obtained by consecutive proteolysis of two larger peptides of 115 AA and 90 AA&#44; respectively&#46;</p><p class="elsevierStylePara">&#191; All carboxi-terminal fragments bear the C-terminal portion and lack a series of AA at the N-terminal position&#46; They are categorized into two groups&#58;</p><p class="elsevierStylePara">1&#46; The larger ones&#44; &#171;N-truncated&#187;&#44; have lost a series of AA at any place of the segment comprised between AA 1 to 34&#46; Their existence has been discovered within the last 5 years<span class="elsevierStyleSup">5</span> and have been named &#171;PTH not 1-84&#187; &#40;fig&#46; 1a&#41;&#46;</p><p class="elsevierStylePara">2&#46; There is another group of C-terminal fragments&#58; these are lacking a segment beyond AA 34 and their N structure begins at positions 34&#44; 37&#44; 41&#44; and 43&#46; These fragments are classically named &#171;C-terminal&#187; &#40;fig&#46; 1a&#41;&#46;</p><p class="elsevierStylePara">&#191; Another recently discovered fragment is termed &#171;amino PTH&#187; and has got an AA sequence similar to that of the intact molecule &#40;1-84&#41;&#44; although it presents a phosphorylation at AA 17&#46;<span class="elsevierStyleSup">6</span> Its function is unknown&#46; It has recently been observed that it is present in higher proportions among patients with parathyroid carcinoma and among patients with primary and secondary severe hyperparathyroidism&#46;<span class="elsevierStyleSup">7</span></p><p class="elsevierStylePara">Given that the C-terminal fragments are biologically active and act through different receptors&#44; some authors have proposed the term &#171;parathyroid polyhormone&#187;&#46;<span class="elsevierStyleSup">8</span> These parathyroid peptides have different actions and regulation mechanisms and metabolism&#46;</p><p class="elsevierStylePara">Intact PTH or the 1-84 fragment account for the classical functions on the bone and kidney and on the &#171;vitamin D-1-alpha-hydroxilase&#187; enzyme&#44; inducing the synthesis of calcitriol&#46; All of these actions share a common objective&#58; to raise plasma calcium levels&#46; Within the parathyroid gland&#44; the Calcium-sensing receptor &#40;CaSR&#41;<span class="elsevierStyleSup">9</span> is directly implicated in the mechanism responsible for the modulation of parathyroid hormone release depending on the extracellular calcium level&#46; Thus&#44; during hypocalcaemic conditions&#44; PTH synthesis and release are stimulated&#46; Hyperphosphatemia is another potent stimulating factor for PTH synthesis and release&#46; By contrast&#44; calcitriol&#44; through its receptor &#40;VDR&#41;&#44; has an inhibitory effect&#46; The classical actions of PTH 1-84 are mediated through a common PTH receptor &#40;PTHR1&#41; and PTH-related protein &#40;PTH rP&#41;&#44; which is present in many tissues&#46; The amino-terminal sequence&#44; constituted by the first 34 AA &#40;N-terminal structure&#41;&#44; is necessary for its action&#46; The interaction between the amino terminal portion with the PTHR1 receptor activates the protein kinase A and C pathways at target tissues&#46;</p><p class="elsevierStylePara">In experimental studies&#44; it has been observed that the fragments termed &#171;no-1-84&#187;&#44; among which the most abundant one is fragment 7-84&#44; have antagonistic biological effects to those of the intact molecule&#46; Indeed&#44; they have hypocalcaemic&#44; hyperphosphatemic&#44; and hypophosphaturic effects&#46; On the other hand&#44; they counteract the hypercalcaemic effect of PTH &#40;1-34&#41; and of PTH &#40;1-84&#41;&#46; Besides&#44; they inhibit vitamin D-induced osteoclastogenesis&#46;<span class="elsevierStyleSup">10</span> All the carboxi-terminal-type fragments of the PTH molecule bind to a new type of receptor of the hormone in bone cells &#40;CPTHR&#41;&#44; which is different from the PTHR1 receptor that requires the 1-34 amino terminal portion of intact PTH to get activated&#46;<span class="elsevierStyleSup">11</span></p><p class="elsevierStylePara">In vivo studies have been carried out in parathyroidectomized rats&#46; The administration of PTH 7-84 decreases serum calcium and phosphate levels and inhibits PTH 1-84-induced phosphaturia&#44; suggesting that it promotes calcium and phosphate entry into the bone&#46;<span class="elsevierStyleSup">11</span> Slatopolsky et al&#46;<span class="elsevierStyleSup">12</span> showed that thyro-parathyroidectomized rats become hypercalcaemic when they are administered PTH 1-84 and the 1-34 fragment &#40;Teriparatide&#41;&#44; and that simultaneous administration of PTH 7-84 blocks this effect and induces hypocalcaemia&#46; They also showed that the administration of PTH 7-84 is accompanied by a decrease in the number of osteoclasts and osteoblasts and that PTH 1-84-induced bone formation is abrogated when PTH 7-84 is administered simultaneously&#44; thus seeming that the differences induced in serum calcium levels are due to a direct effect on the bone&#46; The authors propose the interesting hypothesis that accumulation of these fragments during uremia may be responsible in part of skeletal resistance to PTH&#46;<span class="elsevierStyleSup">12</span></p><p class="elsevierStylePara">The actions of the carboxi-terminal fragments &#40;including the &#171;not 1-84&#187;&#41; have not yet been identified under physiological or pathological conditions&#46; It is likely that the biological effect may be more relevant during renal failure since they might reach higher circulating levels&#46; It has experimentally been shown that under acute hypocalcaemic conditions&#44; PTH 1-84 excretion is favored over that of carboxi-terminal fragments&#44; and that the induction of acute hypercalcaemia reverses the ratio&#46; Under chronic hypocalcaemia conditions&#44; the higher the amount of PTH needed to maintain the calcium level &#40;for instance&#44; in chronic renal failure with vitamin D deficiency&#41;&#44; the higher the amount of PTH 1-84 is secreted at any calcium level and the lower the carboxi-terminal fragments are&#46; It happens the same way in the opposite situation&#46; The lower the amount of PTH needed &#40;for instance&#44; in vitamin D-induced hypercalcaemia&#41;&#44; the lower the amount of PTH 1-84 is secreted and the higher the carboxi-terminal fragments are&#46;<span class="elsevierStyleSup">10</span> Therefore&#44; given that the changes in serum calcium levels regulate the PTH 1-84&#47;C-PTH ratio&#44; secreted at the parathyroid glands&#44; it seems logical to deduce that the carboxi-terminal fragments must have some physiological role&#46;<span class="elsevierStyleSup">13&#44; 14</span></p><p class="elsevierStylePara">Carboxi-terminal fragments act through a receptor &#40;CPTHR&#41; other than PTHR1&#44; which has not being well defined or cloned yet&#46; It has been shown to be present on the cytoplasmic membrane of chicken renal cells&#44; rat osteosarcoma cells&#44; and osteocyte-like cells of mouse bone&#46; These PTH R1-deficient cells have been used to show the affinity of carboxiterminal fragments for this receptor&#46; To date&#44; there are no data in vivo showing the existence of such receptor&#46;<span class="elsevierStyleSup">15&#44; 16</span></p><p class="elsevierStylePara">The regulation and metabolism of the different fragments condition their plasma levels&#46; In healthy individuals&#44; the amount of circulating C-PTH is very much higher &#40;80&#37;&#41; than that of the intact molecule &#40;20&#37;&#41;&#46; This disproportion is likely justified by the shorter half-life of the latter &#40;5-8 minutes&#41;&#46; The carboxi-terminal fragments are cleared by the kidney and accumulate when there is a decreased in glomerular filtration rate&#46; So that in renal failure this type of fragments&#44; which proportion is of 95&#37;&#44; accumulates&#46;<span class="elsevierStyleSup">14</span> Figure 2 shows the different proportions of circulating PTH fragments in healthy individuals and in renal failure&#46;</p><p class="elsevierStylePara">The release and metabolism of the different PTH fragments is illustrated in an integrated way in figure 3&#46; The parathyroid gland releases PTH 1-84 and C-PTH fragments in amounts proportional to serum calcium levels&#46; Under hypocalcaemia the proportion of PTH 1-84 released is higher&#44; and by contrast hypocalcaemia increases the amount of released C-PTH fragments&#46; All of them exert their effect on the bone by interacting with their specific receptors &#40;PTHR1 o CPTHR&#41; or are cleared by the kidney or the liver&#46; PTH 1-84 is rapidly degraded by liver Kupffer cells into a series of carboxi-terminal fragments identical to those secreted by the parathyroid gland&#44; which re-enter into the bloodstream&#46;<span class="elsevierStyleSup">13</span></p><p class="elsevierStylePara">Given that the existence of many of these PTH fragments was unknown until relatively recent dates&#44; the available assays for quantifying PTH 1-84 presented&#44; and still present&#44; crossed values with other parathyroid peptides&#46; This fact may represent an important clinical problem when assessing the situation of the levels of this hormone for establishing a therapy&#44; especially in the case of patients with chronic renal disease&#46;</p><p class="elsevierStylePara">The first determinations of serum PTH levels were carried out by radio-immune analysis &#40;RIA&#41; around the year 1980&#46; These assays were mounted at the same laboratories where the antibodies were generated and the hormone was labeled with <span class="elsevierStyleSup">125</span>I&#46;</p><p class="elsevierStylePara">In the assay an anti-PTH antibody was used detecting different fragments of the hormone depending on the site of it being recognized&#46; Thus&#44; there were radio-immune analyses for amino-terminal&#44; intermediate&#44; and carboxi-terminal PTH fragments&#46; The carboxi-terminal fragments were the ones most commonly used&#44; although as shown in figure 1b&#44; all circulating PTH fragments besides PTH 1-84 were assessed&#44; so that the true value of physiologically active &#40;&#171;intact&#187;&#41; PTH were highly overestimated&#44; especially in patients with renal failure in whom the proportion of circulating C-terminal fragments was much higher than in subjects with normal renal function&#46;</p><p class="elsevierStylePara">This situation was improved at the laboratories because kits for PTH determination started to be commercially available&#44; so that there was no need for labeling the hormone or creating the antibodies to carry out the determination&#44; although the problem of levels overestimation still was the same&#46; These assays have been called first generation assays &#40;fig&#46; 1b&#41;&#46;</p><p class="elsevierStylePara">An important change occurred in 1987<span class="elsevierStyleSup">17</span> when the Nichols Institute Diagnostic Inc developed an immune-radiometric assay &#40;IRMA&#41; to detect PTH&#44; the first of the so-called analysis of &#171;intact PTH&#187;&#46; The assay used two antibodies&#58; one directed against the amino-terminal region &#40;1-34 epitope&#41; and the other one against the carboxi-terminal region &#40;39-84&#41;&#46; In order to be determined&#44; a fragment has to simultaneously bind to both antibodies&#46; Since at that time the existence of the &#171;not 1-84&#187; PTH fragments was unknown&#44; which have been discovered more recently&#44; 5 as well as of the &#171;amino-PTH&#187; fragment&#44; 6 the general believe was that only intact PTH 1-84 values were being determined&#44; and thus of the physiologically active hormone&#46;</p><p class="elsevierStylePara">In theory&#44; the assay was so perfect that from the several studies performed comparing histomorphometry with PTH levels determined by means of Nichols&#191;IRMA<span class="elsevierStyleSup">18-20</span> the &#171;National Kidney Foundation&#47;Kidney-Dialysis Outcomes Quality Initiative &#40;NKF&#47;K-DOQI&#41;&#187; guidelines were elaborated<span class="elsevierStyleSup">21</span> recommending to maintain PTH levels in patients with renal osteodystrophy between 150 and 300 ng&#47;L&#46;</p><p class="elsevierStylePara">Figure 1c shows all the PTH fragments detected by IRMAs called &#171;intact PTH&#187;&#46; As it may be observed&#44; in addition to PTH 1-84 the &#171;not 1-84&#187; fragments and &#171;amino-PTH&#187; are also detected&#44; excluding only from the determination the Cterminal PTH fragments&#46;</p><p class="elsevierStylePara">Several commercial firms developed their own IRMA-type or electrochemiluminescent kits of the so-called &#171;intact-PTH&#187;&#46; Generally all of them use antibodies directed against the same epitopes as the one used by Nichols&#44; with the exception of the assay by Roche called Elecsys&#44; which uses antibodies against the PTH regions 26-32 and 55-64 and which is the only one not detecting the amino-PTH fragment but yes all the &#171;not 1-84&#187; fragments&#44; similar to the other assays of the like from other commercial firms&#46; These assays have been termed 2d generation assays &#40;fig&#46; 1c&#41;&#46;</p><p class="elsevierStylePara">Since the discovery of &#171;not 1-84&#187; PTH fragments&#44; the manufacturer Nichols &#40;that is no longer in the market&#41; and other manufacturers such as Scantibodies&#44; developed new methods with two antibodies in which they still used the antibody directed against the classical carboxi-terminal region and a new one directed against the 4-5 first AA within the amino-terminal region of the PTH molecule&#44; so that most of &#171;not 1-84&#187; fragments were no longer detected&#44; although the &#171;amino-terminal &#187; fragment was still recognized&#46; Figure 1d shows the fragments detected by this type of assays&#44; which have been termed third generation assays&#44; or of &#171;bio-PTH&#187; detection or &#171;whole PTH&#187; detection&#46; As it may be easily deduced&#44; the sample analysis by means of a third generation assay offers much lower values than the use of a second generation assay since not all &#171;not 1-84&#187; fragments are being detected&#46; Its determination has not become generalized in clinical practice because it is a technically demanding method&#46; Another limitation to translate it into the clinical practice is that there are no studies correlating its values with bone histopathology in chronic renal disease&#44; by contrast with &#171;intact PTH&#187;&#46;<span class="elsevierStyleSup">22&#44; 23</span> On the other hand&#44; the fact that &#171;bio-PTH&#187; and &#171;Intact PTH&#187; levels closely correlate has prevented the widespread use of the former&#46; Some authors proposed that the PTH 1-84&#47;&#187;whole&#187; PTH ratio could be useful in the differential diagnosis between low and high bone turnover&#44; although the studies carried out in short patient series have not met the expectancies&#46;<span class="elsevierStyleSup">24&#44; 25</span></p><p class="elsevierStylePara">In this way&#44; in the case that quantification of bio-PTH or whole PTH is not feasible in routine clinical practice&#44; we should be aware that the PTH levels provided by the laboratory have been quantified by means of a second generation assay and thus it corresponds to the sum of PTH 1-84 and &#171;not 1-84&#187; PTH &#40;and in some cases also of amino-PTH&#44; which is the minority&#41;&#44; which are parathyroid peptides with antagonistic effects&#46;</p><p class="elsevierStylePara">In addition to this serious problem of overestimation of the true PTH 1-84 value&#44; there is another problem further complicating the use of the results from these assays by the clinicians&#58; the lack of homogeneous calibration of the determinations between the different manufacturers&#46; Since they do not use the same PTH standards&#44; the numerical results with the same sample may significantly vary with the different techniques used&#44; so that the reference interval of &#171;150-300 ng&#47;L&#187; proposed by the K&#47;DOQI guidelines is no longer valid&#46; JC Souberbielle et al&#46;<span class="elsevierStyleSup">22</span> have confirmed this in an excellent work published in 2006&#46;</p><p class="elsevierStylePara">This inter-method variability makes that&#44; depending on the method used&#44; there is a different percentage of patients requiring pharmacological treatment or even parathyroidectomy&#44; provided that we assume that the values from our laboratory correspond to those used in the K&#47;DOQI guidelines&#46; This methodological error implies inappropriate clinical decision-making&#44; which entails repercussions on health and a considerable financial impact due to the excessive prices of the drugs used for treating hyperparathyroidism&#46;<span class="elsevierStyleSup">26</span></p><p class="elsevierStylePara">Given all this&#44; under the auspices of the Spanish Society of Nephrology&#44; the PTH Measurement Working Group comprised by experts on mineral metabolism and on clinical analyses&#44; has carried out a survey among the Spanish Nephrology Departments in order to know the methods used in our country&#46; Given the existence of high variability &#40;fig&#46; 4&#41;&#44; this Group also considered calculating the inter-method variability in order to provide nephrologists with the appropriate correction factors that should be applied to obtain the same values as with the use of Allegro intact PTH by Nichols &#40;that is the one used for the K&#47;DOQI reference ranges&#41; and with the &#171;bio PTH&#187; by Scantibodies&#46; Although this work is still on going&#44; we already have available the preliminary results that we present since they may be useful in clinical practice&#46; Table 1 shows the results obtained when analyzing PTH levels in 150 hemodialysis patients in whom PTH was simultaneously determined at the laboratories of the Fundaci&#243;n Jim&#233;nez D&#237;az Hospital&#44; La Paz Hospital&#44; and G&#243;mez Ulla Hospital&#44; by means of the six most commonly used methods in our country&#46; It is striking the high inter-method variability that makes K&#47;DOQI references invalid&#46; We&#44; the nephrologists&#44; should from now on be informed of the method applied by our reference laboratory in order to apply the corresponding correction factors&#46; This will allow the clinicians to keep on using the same references and guidelines until there will exist other valid alternatives&#46; <br></br></p>"
    "pdfFichero" => "P-E-S-A491-EN.pdf"
    "tienePdf" => true
    "bibliografia" => array:2 [
      "titulo" => "Bibliography"
      "seccion" => array:1 [
        0 => array:1 [
          "bibliografiaReferencia" => array:26 [
            0 => array:3 [
              "identificador" => "bib1"
              "etiqueta" => "1"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Díez Pérez A, Puig Manresa J,Martínez Izquierdo MT, Nogués Solan X, Vivancos Lleida J. Hiperparatiroidismo primario. En: Patología ósea metabólica. Ed: S Serrano, J Aubia y ML Mariñoso. Sandoz SAE; Barcelona, 1990."
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            1 => array:3 [
              "identificador" => "bib2"
              "etiqueta" => "2"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Collip JB. The extraction of a parathyroid hormone which will prevent or control parathyroid tetany and which regualtes the level of blood calcium. J Biol Chem 1925; 63: 395-438."
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            2 => array:3 [
              "identificador" => "bib3"
              "etiqueta" => "3"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Rodríguez M, Nemeth E, Martin. The calcium-sensing receptor: a key factor in the pathogenesis of secondary hyperparathyroidism. Am J Physiol Renal Physiol 2005; 288: F253-64. <a href="http://www.ncbi.nlm.nih.gov/pubmed/15507543" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            3 => array:3 [
              "identificador" => "bib4"
              "etiqueta" => "4"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Stubbs J, Liu S, Quarles LD. Role of fibroblast growth factor 23 in phosphate homeostasis and pathogenesis of disordered mineral metabolism in chronic kidney disease. Semin Dial 2007; 20: 302-8. <a href="http://www.ncbi.nlm.nih.gov/pubmed/17635819" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            4 => array:3 [
              "identificador" => "bib5"
              "etiqueta" => "5"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "D¿Amour P, Brossard JH, Rousseau L y cols. Structure of non-(1-84) PTH fragments secreted by parathyroid glands in primary and secondary hyperparathyroidism. Kidney Int 2005; 68: 998-1007. <a href="http://www.ncbi.nlm.nih.gov/pubmed/16105030" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            5 => array:3 [
              "identificador" => "bib6"
              "etiqueta" => "6"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "D¿Amour P, Brossard JH, Rousseau L y cols. Amino-terminal form of parathyroid hormone (PTH) with immunologic similarities to hPTH (1-84) is overproduced in primary and secondry hyperparathyroidism. Clin Chem 2003; 49: 2037-2044. <a href="http://www.ncbi.nlm.nih.gov/pubmed/14633875" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            6 => array:3 [
              "identificador" => "bib7"
              "etiqueta" => "7"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "D¿Amour P. Circulating PTH molecular forms: What we know and what we don¿t. Kidney Int 2006; 70: S29-S33."
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            7 => array:3 [
              "identificador" => "bib8"
              "etiqueta" => "8"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Nemeth EF. The parathyroid polyhormone hypotesis revisited. Kidney Int 2006; 70: 522."
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            8 => array:3 [
              "identificador" => "bib9"
              "etiqueta" => "9"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Brown EM, Gamba G, Riccardi D y cols. Cloning and characterization of an extracellular Ca2 -sensing receptor from bovine parathyroid. Nature 1993; 366: 575-580. <a href="http://www.ncbi.nlm.nih.gov/pubmed/8255296" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            9 => array:3 [
              "identificador" => "bib10"
              "etiqueta" => "10"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Nguyen-Yamamoto L, Rousseau L, Brossard JH y cols. Synthetic carboxyl- terminal fragments of PTH decrease ionized calcium concentration in rats by acting on a receptor different from the PTH/PTHrP receptor. Endocrinology 2001; 142: 136-139."
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            10 => array:3 [
              "identificador" => "bib11"
              "etiqueta" => "11"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Divieti P, John MR, Juppner H, Bringhurst FR. Human PTH-(7-84) inhibits bone resorption in vitro via actions independent of the type 1 PTH/PTHrP receptor. Endocrinology 2002; 143: 171-176. <a href="http://www.ncbi.nlm.nih.gov/pubmed/11751606" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            11 => array:3 [
              "identificador" => "bib12"
              "etiqueta" => "12"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Slatopolsky E, Finch E, Clay P, Martin D, Sicard G, Singer G, Gao P, Cantor T, Dusso A. A novel mechanism for skeletal resistance in uremia. Kidney Int 2000; 58: 753-761. <a href="http://www.ncbi.nlm.nih.gov/pubmed/10916099" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            12 => array:3 [
              "identificador" => "bib13"
              "etiqueta" => "13"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Murray TM, Rao LG, Divieti P, Bringhurst FR. Parathyroid Hormone Secretion and Action: Evidencefor Discrete Receptors for the Carboxyl- Terminal Region and Related Biological Actions of Carboxyl-Terminal Ligands. Endocrine Rev 2005; 26 (1): 78-113."
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            13 => array:3 [
              "identificador" => "bib14"
              "etiqueta" => "14"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Ureña Torres P. The need for reliable serum parathyroid hormone measurements. Kidney Int 2006; 70: 240-243. <a href="http://www.ncbi.nlm.nih.gov/pubmed/16838038" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            14 => array:3 [
              "identificador" => "bib15"
              "etiqueta" => "15"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Nguyen-Yamamoto L, Rousseau L, Brossard JH y cols. Synthetic carboxyl- terminal fragments of PTH decrease ionized calcium concentration in rats by acting on a receptor different from the PTH/PTHrP receptor. Endocrinology 2001; 142: 136-139."
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            15 => array:3 [
              "identificador" => "bib16"
              "etiqueta" => "16"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Dieveti P, Geller AL, Suliman G. Receptors Specific for the Carboxyl- Terminal Region of Parathyroid Hormone on Bone-Derived Cells: determinants of Ligand Binding and Bioactivity. Endocrinology 2005; 146: 1863-1870."
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            16 => array:3 [
              "identificador" => "bib17"
              "etiqueta" => "17"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Nussbaum S, Zahradnik R, Lavigne J y cols. Highly sensitive two-site immunoradiometric assay of parathyrin, and its clinical utility in evaluating patients wth hypercalcemia. Clin Chem 1987; 33: 1364-1367. <a href="http://www.ncbi.nlm.nih.gov/pubmed/3608153" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            17 => array:3 [
              "identificador" => "bib18"
              "etiqueta" => "18"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Sherrard DJ, Hercz G, Pei Y y cols. The spectrum of bone disease in endstage renal failure- an evolving disorder. Kidney Int 1993; 43: 436-442. <a href="http://www.ncbi.nlm.nih.gov/pubmed/8441240" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            18 => array:3 [
              "identificador" => "bib19"
              "etiqueta" => "19"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Hercz G, Pei Y, Geenwood y cols. Aplastic osteodistrophy without aluminium: the role of «supressed» parathyroid function. Kidney Int 1993; 44: 860-866. <a href="http://www.ncbi.nlm.nih.gov/pubmed/8258962" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            19 => array:3 [
              "identificador" => "bib20"
              "etiqueta" => "20"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Wang M, Hercz G, Sherrard D y cols. Relationship between intact 1- 84 parathyroid hormone and bone histomorphometric parameters in dialysis patients without aluminium toxicity. Am J Kidney Dis 1995; 26: 836-844. <a href="http://www.ncbi.nlm.nih.gov/pubmed/7485142" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            20 => array:3 [
              "identificador" => "bib21"
              "etiqueta" => "21"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "K/DOQI guidelines for the management of renal osteodistrophy. Am J Kidney Dis 2003; 42 (Supl. 3): S1-S201. <a href="http://www.ncbi.nlm.nih.gov/pubmed/14520607" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            21 => array:3 [
              "identificador" => "bib22"
              "etiqueta" => "22"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Souberbielle JC, Boutten A, Carlier MC y cols. Inter-mehod variability in PTH measurement: implication in the care of CKD patients. Kidney Int 2006; 70: 345-350. <a href="http://www.ncbi.nlm.nih.gov/pubmed/16788691" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            22 => array:3 [
              "identificador" => "bib23"
              "etiqueta" => "23"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Torres A, Lorenzo V, Hernández D, Rodríguez JC, Concepción MT, Rodríguez AP, Hernández A, De Bonis E, Darias E, González-Posada JM, Losada M, Rufino M, Felsenfeld AJ, Rodríguez M. Bone disease in predialysis, hemodialysis and CAPD patients: evidence of a better bone response to PTH. Kidney Int 1995; 47: 1434-1442. <a href="http://www.ncbi.nlm.nih.gov/pubmed/7637272" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            23 => array:3 [
              "identificador" => "bib24"
              "etiqueta" => "24"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Coen G, Bonucci E, Ballanti P, Balducci A,Calabria S,Nicolai GA, Fischer MS, Lifrieri F, Manni M, Morosetti M, Moscaritolo E, Sardella D. PTH 1-84 and PTH «7-84» in the noninvasive diagnosis of renal bone disease. Am J Kidney Diseases 2002; 40: 348-354."
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            24 => array:3 [
              "identificador" => "bib25"
              "etiqueta" => "25"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Cantor T, Yang Z, Caraiani N, Ilamathi E. Lack of comparability of intact parathyroid hormone measurements among comercial assays for end-stage renal disease patients: implication for treatment decisions. Clin Chem 2006; 52: 1771-1776. <a href="http://www.ncbi.nlm.nih.gov/pubmed/16858070" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            25 => array:3 [
              "identificador" => "bib26"
              "etiqueta" => "26"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Foley RN, Li S, Liu J, Gilbertson DT, Chen SC, Collins AJ. The fall and rise of parathyroidectomy in US hemodialysis patients, 1992 to 2002. J Am Soc Nephrol 2005; (1): 210-218."
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
          ]
        ]
      ]
    ]
  ]
  "idiomaDefecto" => "en"
  "url" => "/20132514/0000002800000002/v0_201502091614/X2013251408033088/v0_201502091614/en/main.assets"
  "Apartado" => array:4 [
    "identificador" => "35429"
    "tipo" => "SECCION"
    "en" => array:2 [
      "titulo" => "Editorials"
      "idiomaDefecto" => true
    ]
    "idiomaDefecto" => "en"
  ]
  "PDF" => "https://static.elsevier.es/multimedia/20132514/0000002800000002/v0_201502091614/X2013251408033088/v0_201502091614/en/P-E-S-A491-EN.pdf?idApp=UINPBA000064&text.app=https://revistanefrologia.com/"
  "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X2013251408033088?idApp=UINPBA000064"
]
Article information
ISSN: 20132514
Original language: English
DOI:
The statistics are updated each day
Year/Month Html Pdf Total
2024 November 7 11 18
2024 October 72 60 132
2024 September 59 40 99
2024 August 72 75 147
2024 July 63 38 101
2024 June 68 41 109
2024 May 78 34 112
2024 April 58 32 90
2024 March 39 24 63
2024 February 39 30 69
2024 January 40 33 73
2023 December 44 32 76
2023 November 39 35 74
2023 October 55 51 106
2023 September 67 36 103
2023 August 54 34 88
2023 July 67 29 96
2023 June 71 23 94
2023 May 58 35 93
2023 April 50 31 81
2023 March 43 27 70
2023 February 48 19 67
2023 January 73 28 101
2022 December 67 36 103
2022 November 54 32 86
2022 October 66 57 123
2022 September 63 46 109
2022 August 63 48 111
2022 July 50 43 93
2022 June 45 25 70
2022 May 61 37 98
2022 April 70 41 111
2022 March 75 51 126
2022 February 67 42 109
2022 January 71 33 104
2021 December 53 38 91
2021 November 65 44 109
2021 October 90 38 128
2021 September 45 32 77
2021 August 51 41 92
2021 July 59 42 101
2021 June 43 30 73
2021 May 77 38 115
2021 April 110 69 179
2021 March 80 34 114
2021 February 90 13 103
2021 January 58 18 76
2020 December 53 20 73
2020 November 37 15 52
2020 October 37 16 53
2020 September 37 21 58
2020 August 36 11 47
2020 July 49 10 59
2020 June 67 17 84
2020 May 71 14 85
2020 April 77 23 100
2020 March 81 18 99
2020 February 111 23 134
2020 January 100 29 129
2019 December 104 25 129
2019 November 148 32 180
2019 October 94 19 113
2019 September 83 24 107
2019 August 69 10 79
2019 July 44 22 66
2019 June 28 7 35
2019 May 27 12 39
2019 April 44 26 70
2019 March 22 17 39
2019 February 13 21 34
2019 January 19 12 31
2018 December 50 31 81
2018 November 111 12 123
2018 October 73 11 84
2018 September 73 14 87
2018 August 40 9 49
2018 July 38 15 53
2018 June 31 13 44
2018 May 31 19 50
2018 April 45 9 54
2018 March 38 21 59
2018 February 34 4 38
2018 January 30 13 43
2017 December 50 10 60
2017 November 37 5 42
2017 October 36 10 46
2017 September 26 15 41
2017 August 28 9 37
2017 July 23 27 50
2017 June 30 10 40
2017 May 45 18 63
2017 April 25 7 32
2017 March 19 46 65
2017 February 23 5 28
2017 January 16 5 21
2016 December 39 8 47
2016 November 48 5 53
2016 October 85 6 91
2016 September 92 2 94
2016 August 144 1 145
2016 July 122 7 129
2016 June 122 0 122
2016 May 128 0 128
2016 April 81 0 81
2016 March 76 0 76
2016 February 64 0 64
2016 January 99 0 99
2015 December 114 0 114
2015 November 80 0 80
2015 October 73 0 73
2015 September 52 0 52
2015 August 69 0 69
2015 July 55 0 55
2015 June 35 0 35
2015 May 49 0 49
2015 April 6 0 6
Show all

Follow this link to access the full text of the article

Idiomas
Nefrología (English Edition)
es en

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?